Patrick O Richard1, Ardalan E Ahmad2, Shaheena Bashir2, Alexandre Zlotta2,3, Bimal Bhindi2, Ricardo Leao2, Madhur Nayan2, Aza Mohammed2, Neil E Fleshner2, Girish S Kulkarni2,4. 1. Division of Urology, Departments of Surgery, Centre Hospitalier Universitaire de Sherbrooke and Centre de Recherche du CHUS, Sherbrooke, QC; Canada. 2. Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON; Canada. 3. Division of Urology, Departments of Surgery, Mount Sinai Hospital and the University of Toronto, Toronto, ON; Canada. 4. Institute for Clinical Evaluative Sciences, Toronto, ON; Canada.
Abstract
INTRODUCTION: Non-muscle-invasive bladder cancer (NMIBC) accounts for 75-85% of all urothelial bladder cancers (UBC). Many UBC patients are also afflicted by diabetes mellitus (DM). It has been postulated that several oral hypoglycemic agents could impact disease-specific survival (DSS), but the data are sparse among NMIBC patients. Our primary objective was to evaluate the impact of metformin on DSS and overall survival (OS) in NMIBC patients. METHODS: This is a retrospective, population-based study that used linked administrative databases to identify diabetic patients ≥66 years who were subsequently diagnosed with NMIBC in Ontario between 1992 and 2012. Cumulative use of metformin and other hypoglycemic agent were calculated before and after NMIBC diagnosis. DSS and OS were estimated using multivariable competing risk and Cox proportional hazards models, respectively. RESULTS: A total of 1742 subjects were included in the study. After a median followup of 5.2 years, 1122 (64%) had died, including 247 (15%) deaths as a result of UBC. On multivariable analysis, cumulative duration of metformin use after NMIBC diagnosis did not appear to impact DSS (hazard ratio [HR] 1.1; 95% confidence interval [CI] 0.92-1.2), whereas glyburide use appeared to have a detrimental effect (HR 1.17; 95% CI 1.02-1.3). None of the other hypoglycemic agents had an impact on OS. CONCLUSIONS: In this large, population-based study, we have provided further evidence that metformin use does not significantly impact DSS among diabetic patients diagnosed with NMIBC. However, our findings demonstrate that glyburide use inversely affects DSS. The detrimental effect of glyburide on DSS will require further validation.
INTRODUCTION: Non-muscle-invasive bladder cancer (NMIBC) accounts for 75-85% of all urothelial bladder cancers (UBC). Many UBCpatients are also afflicted by diabetes mellitus (DM). It has been postulated that several oral hypoglycemic agents could impact disease-specific survival (DSS), but the data are sparse among NMIBC patients. Our primary objective was to evaluate the impact of metformin on DSS and overall survival (OS) in NMIBC patients. METHODS: This is a retrospective, population-based study that used linked administrative databases to identify diabeticpatients ≥66 years who were subsequently diagnosed with NMIBC in Ontario between 1992 and 2012. Cumulative use of metformin and other hypoglycemic agent were calculated before and after NMIBC diagnosis. DSS and OS were estimated using multivariable competing risk and Cox proportional hazards models, respectively. RESULTS: A total of 1742 subjects were included in the study. After a median followup of 5.2 years, 1122 (64%) had died, including 247 (15%) deaths as a result of UBC. On multivariable analysis, cumulative duration of metformin use after NMIBC diagnosis did not appear to impact DSS (hazard ratio [HR] 1.1; 95% confidence interval [CI] 0.92-1.2), whereas glyburide use appeared to have a detrimental effect (HR 1.17; 95% CI 1.02-1.3). None of the other hypoglycemic agents had an impact on OS. CONCLUSIONS: In this large, population-based study, we have provided further evidence that metformin use does not significantly impact DSS among diabeticpatients diagnosed with NMIBC. However, our findings demonstrate that glyburide use inversely affects DSS. The detrimental effect of glyburide on DSS will require further validation.
Authors: Sara Gandini; Matteo Puntoni; Brandy M Heckman-Stoddard; Barbara K Dunn; Leslie Ford; Andrea DeCensi; Eva Szabo Journal: Cancer Prev Res (Phila) Date: 2014-07-01
Authors: Igor Makhlin; Jiaru Zhang; Christopher J Long; Karthik Devarajan; Yan Zhou; Andres J Klein-Szanto; Min Huang; Jonathan Chernoff; Stephen A Boorjian Journal: BJU Int Date: 2010-11-02 Impact factor: 5.588
Authors: Maximilian Burger; James W F Catto; Guido Dalbagni; H Barton Grossman; Harry Herr; Pierre Karakiewicz; Wassim Kassouf; Lambertus A Kiemeney; Carlo La Vecchia; Shahrokh Shariat; Yair Lotan Journal: Eur Urol Date: 2012-07-25 Impact factor: 20.096
Authors: Madhur Nayan; Bimal Bhindi; Julie L Yu; Thomas Hermanns; Aza Mohammed; Robert J Hamilton; Antonio Finelli; Michael A S Jewett; Alexandre R Zlotta; Neil E Fleshner; Girish S Kulkarni Journal: Urol Oncol Date: 2015-06-19 Impact factor: 3.498
Authors: Malte Rieken; Evanguelos Xylinas; Luis Kluth; Joseph J Crivelli; James Chrystal; Talia Faison; Yair Lotan; Pierre I Karakiewicz; Maxine Sun; Harun Fajkovic; Marek Babjuk; Alexander Bachmann; Douglas S Scherr; Shahrokh F Shariat Journal: Urol Oncol Date: 2013-10-17 Impact factor: 3.498
Authors: Lisa Haimerl; Dorothea Strobach; Hanna Mannell; Christian G Stief; Alexander Buchner; Alexander Karl; Tobias Grimm Journal: Int J Clin Pharm Date: 2021-11-01